Tharimmune Raises $1.74 Million to Advance Immunology and Oncology Pipeline
Key Insights
Tharimmune completed a $1.74 million registered direct public offering to fund working capital and general corporate purposes.
The clinical-stage biotechnology company is developing TH104 via a 505(b)2 pathway for opioid-induced respiratory depression (search) in military personnel.
The company's expanded pipeline includes TH104 for chronic pruritus (search) in primary biliary cholangitis (search) and TH023 for autoimmune diseases (search).
Clinical-stage biotechnology company Tharimmune announced the pricing of a $1.74 million registered direct public offering on July 23, 2025, to support its diverse therapeutic pipeline in immunology, inflammation, and oncology. The offering consists of 414,331 shares of common stock and 559,910 pre-funded warrants, along with 974,241 warrants exercisable at $1.66 per share.
Financing Structure and Timeline
The securities were priced at $1.786 per unit, with each unit comprising one share of common stock or pre-funded warrant plus one common warrant. President Street Global (search), LLC served as the exclusive placement agent on a best-efforts basis. The offering is expected to close on or about July 25, 2025, subject to customary closing conditions.
Tharimmune intends to use the net proceeds for working capital and general corporate purposes. The offering was conducted under a shelf registration statement (File No. 333-270684) that became effective on March 24, 2023.
Lead Asset Development
Tharimmune's primary clinical asset, TH104, is being developed through a 505(b)2 regulatory pathway for treating respiratory and nervous system depression (search) in military personnel and chemical incident responders exposed to high-potency opioid-contaminated environments. This specialized indication addresses a critical unmet medical need in occupational safety for first responders and military operations.
Expanding Therapeutic Pipeline
Beyond its lead indication, TH104 is being explored for additional therapeutic applications, including chronic pruritus (search) in primary biliary cholangitis (search), a rare liver disease that causes severe itching. The company is also advancing TH023, described as a novel approach to treating autoimmune diseases (search).
Proprietary Technology Platform
The company's early-stage multispecific biologic platform utilizes proprietary EpiClick Technology to target unique epitopes against multiple solid tumors (search). This platform represents Tharimmune's entry into oncology therapeutics, complementing its immunology and inflammation focus.
Tharimmune has established a license agreement with OmniAb, Inc. to access antibody discovery technology for targeting specified disease markers, enhancing its drug development capabilities across its therapeutic areas.
Regulatory Framework
The common warrants included in the offering are being sold under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. These warrants and underlying shares are not currently registered under federal or state securities laws. Tharimmune has committed to filing a resale registration statement to enable future trading of these securities upon proper registration.